Targeting Exciting Inflammasome Field, NodThera Raises $55m

Among Pioneers Of NLRP3 Inhibitors

 
• By Andrew McConaghie
  
Research_Lab
Research into NLRP3 inhibitors has gained momentum in the last few years

More from R&D

More from Scrip